INFECT Strong together against infections CONTROL Science • Society • Industry

Vaccine development with an emphasis on the cooperation of industry and science

VacoME - Development of vaccines against respiratory and systemic infections in humans and pigs

Dr. Peter Schmid Director Pharma Innovation Ceva Santé Animale, France

GEFÖRDERT VOM





wanzig**2**0


Bundesministerium für Bildung und Forschung



VacoME –

Development of vaccines against respiratory and systemic infections in humans and pigs


- Vaccine research and development
- VacoME as an example of an interdisciplinary One Health approach
 - Objectives
 - Disciplines and working groups involved
 - Results
 - Achievements due to the interdisciplinary One Health approach
- Outlook







Vaccine research and development





Objectives

In a trans-sectoral approach, antigens should be identified which provide broad cross serotype protection against *S. suis*

- Identification of host compartment-specific antigens in S. suis (nasopharynx, lung, blood, CSF)
 - *In vivo* and *ex vivo* proteomics
 - RNAseq analyses
- Recombinant production and purification of potentially immunogenic AG candidates
- Immunoproteome analyses by convalescent sera from pigs
- Immunization with multi-component vaccine prototypes and testing of the protective effect in challenge experiments in pigs
- Identification of *ex vivo* correlates for protective immunity



Disciplines and working groups involved







UNIVERSITÄT LEIPZIG

Vet.med. Fakultät VM

Bacteriology and Mycology



UNIVERSITÄT LEIPZIG

Vet.med. Fakultät VMF

Immunology







Results

The objective of cross serotype protection against *S. suis* was not achieved, but,

- the immunoproteomics application was established and validated;
- a spectral database for *S. suis* was created;
- a large number of *S. suis* proteins have been identified which are differentially expressed *in vivo* (>100) in a compartment-specific manner;
- 52 antigen candidates were identified by immunoproteomics (significant difference between sera from convalescent and susceptible pigs);
- a multicomponent vaccine was produced from 6 antigens;
- this vaccine resulted in high antibody titres but no protection in the challenge test;
- the *S. suis*-induced oxidative burst in blood granulocytes was established as a new *in vitro* correlate of protection.




Achievements due to the interdisciplinary One Health approach

- Immunoproteomics based identification of putative cross-protective antigens
- S. suis-induced oxidative burst in blood granulocytes as an *in vitro* correlate of protection




Immunoproteomics-based approach to identify putative cross-protective antigens



INFE ≪T

New *in vitro* correlate of protection: *S. suis*-induced oxidative burst in blood granulocytes







Outlook

PathoWIKI 2020-2021: Development of pathogen-specific databases (WIKI) for *S. suis* and *S. pneumoniae* as a basis for the analysis and application of OMICS data for vaccine development



Acknowledgements

UNIVERSITÄT GREIFSWALD Wissen lockt. Seit 1456



Sven Hammerschmidt Mohammed Abdullah Franziska Voß & international/national partner

Universitätsmedizin Uwe Völker Denise Dittmar

Petra Hildebrandt Stephan Michalik

Ulrike Mäder

UNIVERSITÄT LEIPZIG

Vet.med. Fakultät VMI

Bacteriology and Mycology

Christoph Baums Christine Weiße Viktoria Rungelrath

UNIVERSITÄT LEIPZIG

Vet.med. Fakultät VM

Immunologie Gottfried Alber Nicole Schütze



Susanne Häußler Astrid Dröge Ariane Khaledi



Volker Florian Beata Jakóbczak



Dominik Driesch Daniela Albrecht-Eckardt Sebastian G. Henkel

GEFÖRDERT VOM







Bundesministerium für Bildung und Forschung

INFE CT CONTROL